Patents by Inventor Thomas Hesson

Thomas Hesson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSAY FOR PCSK9 INHIBITORS
    Publication number: 20120214181
    Abstract: The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 23, 2012
    Inventors: Brian M. Beyer, Thomas Hesson, Hung V. Le, Andrew J. Prongay, Krishna Kalghatgi, Jennifer Joanne Gesell, Richard N. Ingram, Michael R. Ziebell
  • Assay for PCSK9 inhibitors
    Patent number: 8206943
    Abstract: The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: June 26, 2012
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Thomas Hesson, Hung V. Le, Andrew J. Prongay, Krishna Kalghatgi, Jennifer Joanne Gesell, Richard N. Ingram, Michael R. Ziebell
  • Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides
    Patent number: 8034907
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: October 11, 2011
    Assignee: Schering Corp.
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • METHODS FOR CRYSTALLIZING ERK2 POLYPEPTIDES
    Publication number: 20100190231
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Application
    Filed: April 5, 2010
    Publication date: July 29, 2010
    Inventors: JESSIE M. ENGLISH, Thierry Oliver Fischmann, Thomas Hesson, Alan William Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Shane Taremi
  • SOLUBLE, STABLE FORM OF HDM2, CRYSTALLINE FORMS THEREOF AND METHODS OF USE THEREOF
    Publication number: 20100136620
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Application
    Filed: November 18, 2009
    Publication date: June 3, 2010
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • Methods for crystallizing ERK2 polypeptides
    Patent number: 7722718
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: May 25, 2010
    Assignee: Schering Corporation
    Inventors: Jessie English, Thierry Oliver Fischmann, Thomas Hesson, Alan William Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Shane Taremi
  • Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
    Patent number: 7632920
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: December 15, 2009
    Assignee: Schering Corporation
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • ERK2 CRYSTALS
    Publication number: 20080081360
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Application
    Filed: October 17, 2007
    Publication date: April 3, 2008
    Inventors: Jessie English, Thierry Fischmann, Thomas Hesson, Alan Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Taremi
  • ERK2 crystals
    Patent number: 7312061
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: December 25, 2007
    Assignee: Schering Corporation
    Inventors: Jessie English, Thierry Oliver Fischmann, Thomas Hesson, Alan William Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Shane Taremi
  • ERK2 crystals
    Publication number: 20060088924
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Application
    Filed: September 23, 2005
    Publication date: April 27, 2006
    Inventors: Jessie English, Thierry Fischmann, Thomas Hesson, Alan Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Taremi
  • Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
    Publication number: 20050037383
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Application
    Filed: April 9, 2004
    Publication date: February 17, 2005
    Inventors: Shahriar Taremi, Gaolian Xie, Thomas Hesson, Jose Duca, Corey Strickland, William Windsor, Vincent Madison, Rumin Zhang, Paul Reichert